Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA appro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Vogel, Victor G., Costantino, Joseph P., Wickerham, D. Lawrence, Cronin, Walter M., Cecchini, Reena S., Atkins, James N., Bevers, Therese B., Fehrenbacher, Louis, Pajon, Eduardo R., Wade, James L., Robidoux, Andre, Margolese, Richard G., James, Joan, Runowicz, Carolyn D., Ganz, Patricia A., Reis, Steven E., McCaskill-Stevens, Worta, Ford, Leslie G., Jordan, V. Craig, Wolmark, Norman
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935331/
https://ncbi.nlm.nih.gov/pubmed/20404000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0076
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares